$1.4 Billion is the total value of EcoR1 Capital, LLC's 50 reported holdings in Q3 2020. The portfolio turnover from Q2 2020 to Q3 2020 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PLRX | Exit | PLIANT THERAPEUTICS INC | $0 | – | -1,300 | -100.0% | -0.00% | – |
| EQ | Exit | EQUILLIUM INC | $0 | – | -59,014 | -100.0% | -0.01% | – |
| KLDO | Exit | KALEIDO BIOSCIENCES INC | $0 | – | -31,374 | -100.0% | -0.02% | – |
| CRVS | Exit | CORVUS PHARMACEUTICALS INC | $0 | – | -737,612 | -100.0% | -0.15% | – |
| LSACU | Exit | LIFESCI ACQUISITION CORPunit 03/31/2025 | $0 | – | -300,000 | -100.0% | -0.24% | – |
| MGTA | Exit | MAGENTA THERAPEUTICS INC | $0 | – | -450,000 | -100.0% | -0.25% | – |
| PRVL | Exit | PREVAIL THERAPEUTICS INC | $0 | – | -367,218 | -100.0% | -0.40% | – |
| EVLO | Exit | EVELO BIOSCIENCES INC | $0 | – | -1,250,000 | -100.0% | -0.45% | – |
| ACAD | Exit | ACADIA PHARMACEUTICALS INC | $0 | – | -135,413 | -100.0% | -0.48% | – |
| KROS | Exit | KEROS THERAPEUTICS INC | $0 | – | -220,216 | -100.0% | -0.61% | – |
| RLMD | Exit | RELMADA THERAPEUTICS INC | $0 | – | -200,000 | -100.0% | -0.66% | – |
| CRNX | Exit | CRINETICS PHARMACEUTICALS IN | $0 | – | -859,802 | -100.0% | -1.11% | – |
| FULC | Exit | FULCRUM THERAPEUTICS INC | $0 | – | -882,353 | -100.0% | -1.19% | – |
| BMYRT | Exit | BRISTOL-MYERS SQUIBB COright 99/99/9999 | $0 | – | -4,748,300 | -100.0% | -1.26% | – |
| DNLI | Exit | DENALI THERAPEUTICS INC | $0 | – | -733,561 | -100.0% | -1.31% | – |
| FATE | Exit | FATE THERAPEUTICS INC | $0 | – | -619,855 | -100.0% | -1.57% | – |
| CNST | Exit | CONSTELLATION PHARMCETICLS I | $0 | – | -837,885 | -100.0% | -1.86% | – |
| RARE | Exit | ULTRAGENYX PHARMACEUTICAL IN | $0 | – | -519,119 | -100.0% | -3.00% | – |
| DRNA | Exit | DICERNA PHARMACEUTICALS INC | $0 | – | -2,721,993 | -100.0% | -5.11% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-11-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| KURA ONCOLOGY ORD | 32 | Q3 2023 | 10.5% |
| XENCOR ORD | 25 | Q3 2023 | 12.6% |
| ASSEMBLY BIOSCIENCES ORD | 23 | Q3 2020 | 19.0% |
| FIBROGEN ORD | 22 | Q1 2020 | 12.4% |
| PROTHENA ORD | 20 | Q3 2023 | 28.0% |
| IRONWOOD PHARMA CL A ORD | 20 | Q1 2020 | 13.9% |
| GALAPAGOS NV SPON ADR | 19 | Q3 2023 | 12.0% |
| MORPHIC HOLDING ORD | 18 | Q3 2023 | 8.5% |
| ARCUS BIOSCIENCES ORD | 17 | Q1 2022 | 7.1% |
| ANAPTYSBIO INC | 16 | Q3 2023 | 8.3% |
View EcoR1 Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Mersana Therapeutics, Inc. | July 27, 2023 | 19,364,688 | 16.9% |
| TScan Therapeutics, Inc. | June 05, 2023 | 5,000,000 | 11.7% |
| 2seventy bio, Inc. | February 14, 2023 | 1,143,494 | 3.0% |
| Avidity Biosciences, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Surface Oncology, Inc. | February 13, 2023 | 3,924,713 | 6.5% |
| Akouos, Inc.Sold out | February 10, 2023 | 0 | 0.0% |
| Alector, Inc. | February 10, 2023 | 4,056,548 | 4.9% |
| Arcus Biosciences, Inc.Sold out | February 10, 2023 | 0 | 0.0% |
| Gritstone bio, Inc.Sold out | February 10, 2023 | 0 | 0.0% |
| Ovid Therapeutics Inc. | February 10, 2023 | 6,117,400 | 8.7% |
View EcoR1 Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-05-03 |
| SC 13G/A | 2024-04-08 |
| 3 | 2024-03-26 |
| SC 13G/A | 2024-03-26 |
| SC 13G | 2024-03-11 |
| SC 13D | 2024-02-22 |
| SC 13G | 2024-02-16 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View EcoR1 Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.